•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
IXICO CEO Bram Goorden said the company’s first-half trading update reflects a continuation of a 2025 trend reversal, with growth building into 2026. He highlighted a 23% increase in revenue as the headline figure, driven primarily by new contracts and contract extensions, alongside rising volumes and analytics usage.
Goorden said the main drivers of the first-half performance were “more contracts” and “contract extensions,” emphasizing the value delivered to both existing and new clients. He also pointed to increased volume and analytics activity, which he said indicates IXICO’s platform is now operating at a scale-ready level after a period he described as being “subscale.”
He cited a record high in March for revenue linked to analytics, attributing the improvement to increasing volumes and the company’s ability to fully scale its platform.
IXICO’s contract strategy, according to Goorden, remains concentrated on neurological and CNS indications, including Alzheimer’s and Parkinson’s, as well as rare CNS. He said the company has been landing more Alzheimer’s trials, including across other modality spaces, and is further validating blood-based biomarker products.
He also referenced progress in later-stage clinical trials, including phase two and phase three, noting that IXICO announced a major phase three trial win at the end of last year and later secured an extension in phase two.
Looking ahead, Goorden said the company’s near-term focus will be “more of the same,” centered on scaling operations to support revenue and margin improvement. He said IXICO has brought its margin to 53%, describing this as a 4 percentage-point improvement versus the same period last year.
On profitability, he said EBITDA was “just shy of negative half a million” for the half, adding that the company is moving closer to profitability.
Goorden attributed the margin and profitability trajectory to filling the order book. He said the order book is at a record high since several years, at 18.1 million, representing a 38% increase. He said this scale is expected to support further progress toward profitability through the remainder of the year.
Goorden said IXICO’s priorities also include implementing its new TechBio strategy following a fundraising round of 10 million. He said the raise is intended to unlock additional revenue and value drivers, while building on the momentum from the first half.
He described a shift in how the platform is used, saying it will increasingly “live in the hands of other users” in the clinical trial ecosystem beyond IXICO’s internal experts. The approach, he said, involves partnering the platform and generating recurring revenue through licensing and collaboration.
To support licensing and partnerships, Goorden said IXICO needs to standardize and automate the platform so it can integrate with partner organizations. He said the fundraising will enable the required investments.
Goorden pointed to a partnership announced a few weeks earlier with Medidata as an example of the strategy in action. He said Medidata is the largest electronic data capturing provider in the clinical trial space, serving 18 of the 25 big pharma clients, and supporting 80% of all clinical research organizations. He said Medidata’s decision to partner with IXICO’s precision analytics technology reflects the intended combination of IXICO’s analytics capability with Medidata’s reach in the sector.
Goorden concluded by saying the company will continue to celebrate and build on the growth achieved in its core business over the past six months while advancing the TechBio platform partnership strategy.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
